| Literature DB >> 32344708 |
Liang Chen1, Chun Hu2, Molly Hood3, Xue Zhang1, Lu Zhang1, Juntao Kan1, Jun Du1.
Abstract
Novel coronaviruses (CoV) have emerged periodically around the world in recent years. The recurrent spreading of CoVs imposes an ongoing threat to global health and the economy. Since no specific therapy for these CoVs is available, any beneficial approach (including nutritional and dietary approach) is worth investigation. Based on recent advances in nutrients and phytonutrients research, a novel combination of vitamin C, curcumin and glycyrrhizic acid (VCG Plus) was developed that has potential against CoV infection. System biology tools were applied to explore the potential of VCG Plus in modulating targets and pathways relevant to immune and inflammation responses. Gene target acquisition, gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment were conducted consecutively along with network analysis. The results show that VCG Plus can act on 88 hub targets which are closely connected and associated with immune and inflammatory responses. Specifically, VCG Plus has the potential to regulate innate immune response by acting on NOD-like and Toll-like signaling pathways to promote interferons production, activate and balance T-cells, and regulate the inflammatory response by inhibiting PI3K/AKT, NF-κB and MAPK signaling pathways. All these biological processes and pathways have been well documented in CoV infections studies. Therefore, our findings suggest that VCG Plus may be helpful in regulating immune response to combat CoV infections and inhibit excessive inflammatory responses to prevent the onset of cytokine storm. However, further in vitro and in vivo experiments are warranted to validate the current findings with system biology tools. Our current approach provides a new strategy in predicting formulation rationale when developing new dietary supplements.Entities:
Keywords: coronavirus; curcumin; glycyrrhizic acid; immune response; inflammatory response; system biology; vitamin C
Year: 2020 PMID: 32344708 PMCID: PMC7230237 DOI: 10.3390/nu12041193
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Hub targets identified for VCG Plus. VCG Plus, the combination of vitamin C, curcumin and glycyrrhizic acid. VC, vitamin C; CC, curcumin; GA, glycyrrhizic acid.
| GENE_SYMBOL | Name | Distribution |
|---|---|---|
| EP300 | E1A binding protein p300 | CC only |
| VCAM1 | vascular cell adhesion molecule 1 | CC only |
| CCN2 | cellular communication network factor 2 | CC only |
| MYC | MYC proto-oncogene, bHLH transcription factor | CC only |
| VEGFA | vascular endothelial growth factor A | CC only |
| ADIPOQ | adiponectin, C1Q and collagen domain containing | CC only |
| IKBKB | inhibitor of nuclear factor kappa B kinase subunit beta | CC only |
| FN1 | fibronectin 1 | CC only |
| ESR1 | estrogen receptor 1 | CC only |
| MAPK8 | mitogen-activated protein kinase 8 | CC only |
| GSTP1 | glutathione S-transferase pi 1 | CC only |
| FOS | Fos proto-oncogene, AP-1 transcription factor subunit | CC only |
| AKT1 | AKT serine/threonine kinase 1 | CC only |
| IFNB1 | interferon beta 1 | CC only |
| MDM2 | MDM2 proto-oncogene | CC only |
| CXCL1 | C-X-C motif chemokine ligand 1 | CC only |
| CXCL2 | C-X-C motif chemokine ligand 2 | CC only |
| PDGFB | platelet derived growth factor subunit B | CC only |
| AHR | aryl hydrocarbon receptor | CC only |
| CYP2E1 | cytochrome P450 family 2 subfamily E member 1 | CC only |
| EGFR | epidermal growth factor receptor | CC only |
| EGR1 | early growth response 1 | CC only |
| IGF1R | insulin like growth factor 1 receptor | CC only |
| BIRC3 | baculoviral IAP repeat containing 3 | CC only |
| IGFBP3 | insulin like growth factor binding protein 3 | CC only |
| STAT3 | signal transducer and activator of transcription 3 | CC only |
| EGF | epidermal growth factor | CC only |
| IL18 | interleukin 18 | CC only |
| CCND1 | cyclin D1 | CC only |
| MMP9 | matrix metallopeptidase 9 | CC only |
| BCL2L1 | BCL2 like 1 | CC only |
| JUN | Jun proto-oncogene, AP-1 transcription factor subunit | CC only |
| IL10 | interleukin 10 | CC only |
| HMGB1 | high mobility group box 1 | CC_GA_intersect |
| IL6 | interleukin 6 | CC_GA_intersect |
| CREB1 | cAMP responsive element binding protein 1 | CC_GA_intersect |
| IFNG | interferon gamma | CC_GA_intersect |
| BDNF | brain derived neurotrophic factor | CC_GA_intersect |
| MMP2 | matrix metallopeptidase 2 | CC_GA_intersect |
| CCL2 | C-C motif chemokine ligand 2 | CC_GA_intersect |
| CASP9 | caspase 9 | CC_GA_intersect |
| AR | androgen receptor | CC_GA_intersect |
| CASP8 | caspase 8 | CC_GA_intersect |
| SIRT1 | silent mating type information regulation 2 homolog 1 | GA only |
| BMP2 | bone morphogenetic protein 2 | VC only |
| TIMP1 | TIMP metallopeptidase inhibitor 1 | VC only |
| TLR2 | toll like receptor 2 | VC only |
| SPP1 | secreted phosphoprotein 1 | VC only |
| MMP13 | matrix metallopeptidase 13 | VC only |
| NOS3 | nitric oxide synthase 3 | VC only |
| TF | transferrin | VC only |
| RUNX2 | RUNX family transcription factor 2 | VC only |
| EZH2 | enhancer of zeste 2 polycomb repressive complex 2 subunit | VC only |
| CD44 | CD44 molecule | VC only |
| HMOX1 | heme oxygenase 1 | VC_CC_GA_intersect |
| RELA | RELA proto-oncogene, NF-κB subunit | VC_CC_GA_intersect |
| TGFB1 | transforming growth factor beta 1 | VC_CC_GA_intersect |
| PTGS2 | prostaglandin-endoperoxide synthase 2 | VC_CC_GA_intersect |
| NFKBIA | NF-κB inhibitor alpha | VC_CC_GA_intersect |
| NFKB1 | nuclear factor kappa B subunit 1 | VC_CC_GA_intersect |
| CXCL8 | C-X-C motif chemokine ligand 8 | VC_CC_GA_intersect |
| SOD2 | superoxide dismutase 2, mitochondrial | VC_CC_GA_intersect |
| ALB | albumin | VC_CC_GA_intersect |
| TNF | tumor necrosis factor | VC_CC_GA_intersect |
| NOS2 | nitric oxide synthase 2 | VC_CC_GA_intersect |
| CASP3 | caspase 3 | VC_CC_GA_intersect |
| PARP1 | poly (ADP-ribose) polymerase 1 | VC_CC_intersect |
| CTNNB1 | catenin beta 1 | VC_CC_intersect |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | VC_CC_intersect |
| NFE2L2 | nuclear factor, erythroid 2 like 2 | VC_CC_intersect |
| PPARG | peroxisome proliferator activated receptor gamma | VC_CC_intersect |
| IL1B | interleukin 1 beta | VC_CC_intersect |
| MAPK3 | mitogen-activated protein kinase 3 | VC_CC_intersect |
| MAPK1 | mitogen-activated protein kinase 1 | VC_CC_intersect |
| MPO | myeloperoxidase | VC_CC_intersect |
| TLR4 | toll like receptor 4 | VC_CC_intersect |
| COL1A1 | collagen type I alpha 1 chain | VC_CC_intersect |
| AGT | angiotensinogen | VC_CC_intersect |
| APP | amyloid beta precursor protein | VC_CC_intersect |
| HIF1A | hypoxia inducible factor 1 alpha subunit | VC_CC_intersect |
| CDKN1A | cyclin dependent kinase inhibitor 1A | VC_CC_intersect |
| IGF1 | insulin like growth factor 1 | VC_CC_intersect |
| SOD1 | superoxide dismutase 1 | VC_CC_intersect |
| CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | VC_CC_intersect |
| BCL2 | BCL2, apoptosis regulator | VC_CC_intersect |
| TP53 | tumor protein p53 | VC_CC_intersect |
| CAT | catalase | VC_CC_intersect |
| ICAM1 | intercellular adhesion molecule 1 | VC_CC_intersect |
Figure 1Hub target analysis of VCG Plus. A Venn diagram of hub target distribution in VC, CC and GA, respectively (A). PPI network of 88 hub targets of VCG Plus (B). OmicsBean (http://www.omicsbean.cn/) was employed to draw Figure 1A. Cytoscape software (Version 3.6.1) was employed to draw Figure 1B. In Figure 1B, all the targets are represented by nodes, whereas the interaction between the targets are represented by edges. The node size is proportional to the node degree. The intersect targets of VC, CC and GA are represented by green. VCG Plus, the combination of vitamin C, curcumin and glycyrrhizic acid. VC, vitamin C (group1); CC, curcumin (group 2); GA, glycyrrhizic acid (group 3). PPI, protein-protein interaction.
Figure 2Distribution analysis of targets in tissues and systems. The bubble plots were made using JMP software 14.2.0 (SAS institute Inc. USA). Distribution of targets of VCG Plus in system (A), distribution of targets of VC, CC and GA in tissues (B). In Figure 2A, the bubble size is proportional to the targets number, and the shade of bubble is inversely proportional to the p-value. In Figure 2B, the bubble size is proportional to the targets number. The targets distribution of VC is represented by blue bubble, CC is represented by red bubble, and GA are represented by green bubble. VC, vitamin C; CC, curcumin; GA, glycyrrhizic acid.
Figure 3Top 10 gene ontology (GO) terms of biologic process, molecular function and cellular component, respectively. The bubble plot was made using JMP software 14.2.0 (SAS institute Inc. USA). The bubble size is proportional to the targets number, and the shade of bubble is inversely proportional to the p-value.
Figure 4Target immune-related biologic process network. The network was constructed by ClueGo (Latest Version 2.5.6), integrating immune process EBI-Uniport GO annotation database. Only pathways with p < 0.05 are shown. The targets and biologic processes are represented by nodes while the interactions among them are represented by edges. Contribution of VC (vitamin c) in targets and pathways is represented by red, while CC (curcumin) is represented by blue, and GA (glycyrrhizic acid) is represented by green.
Figure 5Target KEGG pathways network of VCG Plus. The network was constructed by ClueGo (Latest Version 2.5.6), integrating the latest KEGG pathway database. The targets and pathways are represented by nodes while the interactions among them are represented by edges. Contribution of VC (vitamin c) in targets and pathways is represented by red, while CC (curcumin) is represented by blue, and GA (glycyrrhizic acid) is represented by green.